DK1713501T3 - Behandling af neurodegenerative sygdomme ved anvendelse af GPR49 - Google Patents

Behandling af neurodegenerative sygdomme ved anvendelse af GPR49

Info

Publication number
DK1713501T3
DK1713501T3 DK04803345T DK04803345T DK1713501T3 DK 1713501 T3 DK1713501 T3 DK 1713501T3 DK 04803345 T DK04803345 T DK 04803345T DK 04803345 T DK04803345 T DK 04803345T DK 1713501 T3 DK1713501 T3 DK 1713501T3
Authority
DK
Denmark
Prior art keywords
gpr49
secretase
interacting molecule
treatment
beta
Prior art date
Application number
DK04803345T
Other languages
English (en)
Inventor
Carsten Hopf
Gerard Drewes
Heinz Ruffner
Original Assignee
Cellzome Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellzome Ag filed Critical Cellzome Ag
Application granted granted Critical
Publication of DK1713501T3 publication Critical patent/DK1713501T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
DK04803345T 2004-01-29 2004-11-29 Behandling af neurodegenerative sygdomme ved anvendelse af GPR49 DK1713501T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP04001894 2004-01-29
EP04001895 2004-01-29
EP04007447 2004-03-26
EP2004004889 2004-05-07
EP2004004891 2004-05-07
PCT/EP2004/013539 WO2005074980A1 (en) 2004-01-29 2004-11-29 Treatment of neurodegenerative diseases by the use of gpr49

Publications (1)

Publication Number Publication Date
DK1713501T3 true DK1713501T3 (da) 2008-05-26

Family

ID=38556372

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04803345T DK1713501T3 (da) 2004-01-29 2004-11-29 Behandling af neurodegenerative sygdomme ved anvendelse af GPR49

Country Status (11)

Country Link
US (1) US20080025969A1 (da)
EP (1) EP1713501B1 (da)
JP (1) JP2007525491A (da)
AT (1) ATE383870T1 (da)
AU (1) AU2004315111B2 (da)
CA (1) CA2554353A1 (da)
DE (1) DE602004011400T2 (da)
DK (1) DK1713501T3 (da)
ES (1) ES2300852T3 (da)
PT (1) PT1713501E (da)
WO (2) WO2005074980A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
ZA200804162B (en) * 2005-11-21 2009-12-30 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
EP2022848A1 (en) * 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
WO2010016766A2 (en) * 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Antibodies recognizing endogenous human lgr5 and/or lgr6
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8604074B2 (en) 2009-01-09 2013-12-10 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
BR112013000414A2 (pt) 2010-07-07 2016-05-17 Univ Texas compostos proneurogênicos
US9701676B2 (en) 2012-08-24 2017-07-11 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9908863B2 (en) 2013-01-10 2018-03-06 Merck Patent Gmbh Piperidinylcarbazoles
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
WO2015070234A2 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
CN111533734A (zh) 2014-07-04 2020-08-14 默克专利股份有限公司 具有抗寄生虫活性的氮杂环庚烷基衍生物和包含它们的药物组合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2089661C (en) * 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
WO1998015828A1 (en) * 1996-10-07 1998-04-16 Scios Inc. Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
EP1146898A1 (en) * 1999-01-22 2001-10-24 Matthew John During Vaccine-mediated treatment of neurological disorders
DE19941039A1 (de) * 1999-08-28 2001-03-01 Boehringer Ingelheim Pharma gamma-Sekretase in vitro Testsystem
GB0005894D0 (en) * 2000-03-10 2000-05-03 Glaxo Group Ltd Assay
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
JP4344519B2 (ja) * 2000-12-28 2009-10-14 旭化成ファーマ株式会社 ＮＦ−κＢ活性化遺伝子
AU2002228316A1 (en) * 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
CA2490278A1 (en) * 2002-06-26 2004-01-22 Cellzome Ag Components of the presenilin-complex
EP1380644A1 (en) * 2002-07-08 2004-01-14 Kylix B.V. The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role
US7056685B1 (en) * 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
US7189539B2 (en) * 2003-11-25 2007-03-13 Bristol-Myers Squibb Company Polynucleotide encoding a human relaxin receptor, HGPRBMY5v1

Also Published As

Publication number Publication date
WO2005074980A1 (en) 2005-08-18
ATE383870T1 (de) 2008-02-15
AU2004315111A1 (en) 2005-08-18
PT1713501E (pt) 2008-04-30
DE602004011400D1 (de) 2008-03-06
US20080025969A1 (en) 2008-01-31
DE602004011400T2 (de) 2009-01-22
WO2005074971A1 (en) 2005-08-18
JP2007525491A (ja) 2007-09-06
ES2300852T3 (es) 2008-06-16
CA2554353A1 (en) 2005-08-18
EP1713501A1 (en) 2006-10-25
AU2004315111B2 (en) 2010-03-04
EP1713501B1 (en) 2008-01-16

Similar Documents

Publication Publication Date Title
DK1713501T3 (da) Behandling af neurodegenerative sygdomme ved anvendelse af GPR49
EA201070247A1 (ru) Ингибиторы протеасом
EA200900959A1 (ru) Ингибиторы мек
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
NO20061122L (no) 2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
NO20080318L (no) Anvendelse av enkelt dose av CD-20-spesifikke bindingsmolekyler
NO20064362L (no) Forbindelser, farmaseutiske sammensetninger og fremgangsmater for anvendelse i behandling av metabolske sykdommer
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE537152T1 (de) Verbindungen, ihre pharmazeutischen zusammensetzungen und ihre verwendung in der behandlung von stoffwechselstörungen
EA200870569A1 (ru) Соединения и способы модуляции fxr
EA200971077A1 (ru) Гетероциклические модуляторы киназы
ATE383337T1 (de) 1-(1h-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1- phenylpropan-2-olderivate und verwandte verbindungen als modulatoren der norepinephrin- (ne-) und der serotonin-(5-ht-) aktivität und der monoaminwiederaufnahme zur behandlung von vasomotorischen symptomen (vms)
EA200702567A1 (ru) Ингибиторы дипептидил пептидазы iv, основанные на пирролопиридине
NO20072199L (no) Trombopoietinaktivitetsmodulerende forbindelser og fremgangsmater
ATE413406T1 (de) Benzothiazol-, thiazolopyridin-, benzooxazol- und oxazolopyridin-derivate als verbindungen zur behandlung von diabetes
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
WO2006034296A3 (en) Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
DE602005027388D1 (de) Malonsäureamidderivate als inhibitoren von g-sekretase zur behandlung von alzheimer-krankheit
EE200400031A (et) Biokeemiliste ühendite kompositsioon, selle kasutamine maatriks-metalloproteinaaside pärssimiseks ning seda sisaldav ravimpreparaat
WO2005119252A3 (en) Modulators of gpr35 for the treatment of metabolic-related disorders